Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down After Earnings Miss

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $23.83, but opened at $22.91. Kestra Medical Technologies shares last traded at $23.34, with a volume of 29,702 shares.

The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period in the previous year, the firm earned ($1.18) EPS.

Analyst Upgrades and Downgrades

A number of research analysts have commented on KMTS shares. Wells Fargo & Company assumed coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an “overweight” rating and a $28.00 price target on the stock. The Goldman Sachs Group initiated coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued a “neutral” rating and a $24.00 price objective for the company. Bank of America initiated coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a “buy” rating and a $30.00 target price on the stock. Piper Sandler began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “overweight” rating and a $27.00 price target for the company. Finally, Stifel Nicolaus began coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued a “buy” rating and a $28.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Kestra Medical Technologies Stock Up 1.3 %

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.